APA (7th ed.) Citation

LM, D., A, G., C, V., E, K., D, C., C, R., . . . H, O. L. (2026). First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France. Drugs - real world outcomes, 13(2), 211. https://doi.org/10.1007/s40801-026-00551-z

Chicago Style (17th ed.) Citation

LM, Dourthe, et al. "First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France." Drugs - Real World Outcomes 13, no. 2 (2026): 211. https://doi.org/10.1007/s40801-026-00551-z.

MLA (9th ed.) Citation

LM, Dourthe, et al. "First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France." Drugs - Real World Outcomes, vol. 13, no. 2, 2026, p. 211, https://doi.org/10.1007/s40801-026-00551-z.